FXR signaling pathway is a valid target for chemoprevention in colorectal cancer

描述（由申请人提供）：结直肠癌（CRC）是美国第三大恶性肿瘤。今年将诊断出15万多例结直肠癌，5万多人将死于这种疾病（http：//ser.cancer.gov/cgi-bin/csr/）。因此，对于治疗和预防CRC的新方法存在未满足的医学需求。胆汁酸在高脂肪饮食的个体中升高，30多年前被认为是结直肠癌的危险因素。有趣的是，熊去氧胆酸，一种对人类来说不是天然的胆汁酸，而是从熊中提取的，实际上已经显示出对结肠直肠癌的化学预防特性。尽管天然胆汁酸与结直肠癌之间存在联系，熊去氧胆酸（UDCA）具有不寻常的化学预防特性，但胆汁酸与结直肠癌之间的机制联系仍然不清楚。拟议的研究重点是法尼醇X受体a（FXRa），一个在肠道中表达的转录因子核受体家族的成员。该受体被胆汁酸激活，并调节参与胆汁酸稳态和细胞分化的靶基因的表达。本研究的主要假设是FXRa信号通路是结直肠癌化学预防的有效靶点。我们已经发现，FXRa的减少在两个独立的结直肠癌小鼠模型中促进肿瘤发生。此外，我们发现回肠胆汁酸结合蛋白（IBABP）与FXR在正反馈回路中起作用，并且是FXR活性所必需的，因此影响IBABP的因素可能会改变FXR的功能，从而影响肿瘤的发病率和生长。我们也有证据表明UDCA与IBABP形成复合物，然后刺激FXRa。总之，这些结果表明，有两种途径靶向FXR途径进行化学预防：直接打击FXR或通过IBABP增加FXR活性。为了验证我们的假设，我们将解决以下问题：1）FXRa是否具有保护肠道免受肿瘤发生的作用？2)FXRa治疗何时适合预防CRC？3)FXRa的小分子激动剂可以预防CRC吗？4)UDCA的化学预防特性是否是其与IBABP结合以及FXRa相应反式激活的结果？5)IBABP单核苷酸多态性是否与结直肠癌的发生和UDCA的疗效相关？这项研究的结果可能会提供新的化学预防方法，以及识别反应亚群的新方法。公共卫生相关性：尽管天然胆汁酸与结直肠癌之间存在联系，熊去氧胆酸（UDCA）具有不寻常的化学预防特性，但胆汁酸与结直肠癌之间的机制联系仍然不清楚。拟议的研究重点是法尼醇X受体a（FXRa），这是一种核受体家族的转录因子，几乎只在肠道中表达，被胆汁酸激活，调节参与胆汁酸稳态的靶基因的表达，并在结直肠癌中下调。主要假设是FXRa信号通路是结直肠癌化学预防的有效靶点。这项研究的结果可能会提供新的化学预防方法，以及识别反应亚群的新方法。

DESCRIPTION (provided by applicant): Colorectal cancer (CRC) is the third-leading malignancy in the United States. This year more than 150,000 cases of colorectal cancer will be diagnosed and more than 50,000 people will die from the disease (http://ser.cancer.gov/cgi-bin/csr/). Consequently there is an unmet medical need for new methods for treating and preventing CRC. Bile acids, which are elevated in individuals with high fat diets, were recognized as risk factors for colorectal cancer more than 30 years ago. Paradoxically, ursodeoxycholic acid, a bile acid that is not natural to humans but which is derived from the bear, has actually shown chemopreventative properties for colorectal cancer. Despite the link between natural bile acids and colorectal cancer, and the unusual chemopreventative properties of ursodeoxycholic acid (UDCA), the mechanistic connections between bile acids and colorectal cancer remain poorly defined. The proposed study focuses on the farnesoid X receptor a (FXRa), a member of the nuclear receptor family of transcription factors that is expressed in the intestinal tract. This receptor is activated by bile acids, and regulates the expression of target genes involved in bile acid homeostasis and cell differentiation. The primary hypothesis of this study is that the FXRa signaling pathway is a valid target for chemoprevention in colorectal cancer. We have found that reduction of FXRa promotes tumorigenesis in a two independent mouse models of colorectal cancer. Moreover, we have found that ileal bile acid binding protein (IBABP) operates in a positive feedback loop with FXR and is necessary for FXR activity, thus factors that influence IBABP are likely to alter the function of FXR and therefore impact tumor incidence and growth. We also have evidence indicating that UDCA forms a complex with IBABP, which then stimulates FXRa. Together these results suggest that there are two routes to targeting the FXR pathway for chemoprevention: hitting FXR directly or by increasing FXR activity through IBABP. To test our hypothesis, we will address the following questions: 1) Does FXRa have a role in protecting the intestine from tumorigenesis? 2) When is FXRa therapy suitable for prevention of CRC? 3) Can small molecule agonists of FXRa prevent CRC? 4) Are the chemopreventative properties of UDCA a result of its binding to IBABP and the corresponding transactivation of FXRa? 5) Is the single nucleotide polymorphism of IBABP associated with the development of CRC and the response to UDCA? Results from this study are likely to provide new methods for chemoprevention, and novel assays for identifying responsive sub-populations. PUBLIC HEALTH RELEVANCE: Despite the link between natural bile acids and colorectal cancer, and the unusual chemopreventative properties of ursodeoxycholic acid (UDCA), the mechanistic connections between bile acids and colorectal cancer remain poorly defined. The proposed study focuses on the farnesoid X receptor a (FXRa), a member of the nuclear receptor family of transcription factors that is expressed almost exclusively in intestinal tract, is activated by bile acids, regulates the expression of target genes involved in bile acid homeostasis, and is down-regulated in colorectal cancer. The primary hypothesis is that the FXRa signaling pathway is a valid target for chemoprevention in colorectal cancer. Results from this study are likely to provide new methods for chemoprevention, and novel assays for identifying responsive sub-populations.